POSTER: Digital Therapeutic For Refractory And Unexplained Chronic Cough: A Proof Of Concept Study
Summary
At CHEST 2025, held in Chicago, Illinois, Laurie Slovarp, PhD, CCC-SLP, professor at the University of Montana and certified speech pathologist, presented a poster on the development of a digital therapeutic designed to improve access to behavioral cough suppression therapy for patients with refractory chronic cough.
Despite recent advances, there are no FDA-approved drugs for refractory/unexplained chronic cough (RCC/UCC). Numerous studies have demonstrated efficacy of cough suppression treatment (CST) by specialty-trained speech-language pathologists (SLPs). While recommended in consensus statements, there is a significant shortage of specialized SLPs to treat the estimated 5-7 million cases of RCC/UCC in the US. We have integrated essential components of CST within the CoughPro cough monitoring application with the purpose of testing proof of concept for a CST digital therapeutic.
